MVMark S. Veselov

Mark S. Veselov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark S. Veselov has a total of 106 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Synthesis and Biological Evaluation of S-, O- and Se-Containing Dispirooxindoles

    by Maksim Kukushkin, Vladimir Novotortsev, Vadim Filatov, Yan Ivanenkov, Dmitry Skvortsov, Mark Veselov, Radik Shafikov, Anna Moiseeva, Nikolay Zyk, Alexander Majouga, et al.

    A series of novel S-, O- and Se-containing dispirooxindole derivatives has been synthesized using 1,3-dipolar cycloaddition reaction of azomethine ylide generated from isatines and sarcosine at the double C=C bond of 5-indolidene-2-chalcogen-imidazolones (chalcogen was oxygen, sulfur or selenium). The cytotoxicity of these dispiro derivatives was evaluated in vitro using different tumor cell lines. Several molecules have demonstrated a considerable cytotoxicity against the panel and showed good selectivity towards colorectal carcinoma HCT116 p53+/+ over HCT116 p53−/− cells. In particular, good results have been obtained for LNCaP prostate cell line. The performed in silico study has revealed MDM2/p53 interaction as one of the possible targets for the synthesized molecules. However, in contrast to selectivity revealed during the cell-based evaluation and the results obtained in computational study, no significant p53 activation using a reporter construction in p53wt A549 cell line was observed in a relevant concentration range.


  • AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models

    by Alexandre V. Ivachtchenko, Yan A. Ivanenkov, Mark S. Veselov, I. M. Okun

    Background: In recent years, 5-hydroxytryptamine subtype 6 receptor (5-HT6 receptor, 5- HT6R) has emerged as a promising therapeutic target for the treatment of neuropathological disorders, including Alzheimer’s disease (AD) and schizophrenia. 5-HT6 receptors were hypothesized to be implicated in the processes of learning, memory, and cognition with 5-HT6R antagonists being effective in animal models of cognition and memory impairment. Several selective 5-HT6R ligands are currently undergoing clinical trials for treatment of AD. Methods: We describe results of preclinical development of a novel and highly selective and potent 5- HT6R antagonist, AVN-322, as a clinical candidate for the treatment of AD to improve concurrent debilitation of memory and cognition in the AD patients, and schizophrenia as a substance with antipsychotic effect. In the manuscript, we present its in vitro and vivo efficacy, ADME, pharmacokinetics in animals and in humans, and toxicity. Results: While having high binding affinity in medium picomolar range, the lead compound demonstrates substantially better selectivity index then the reference drug candidates currently being tested in clinical studies. AVN-322 showed high oral bioavailability and favorable blood-brain barrier (BBB) penetration. In vivo testing revealed its clear cognition enhancing effect. AVN-322 significantly restored both scopolamine- and MK-801-induced cognitive dysfunction and demonstrated antipsychotic potential. Conclusion: Taking into account its good safety profile and favorable pharmacokinetics, AVN-322 can be reasonably considered as a novel drug candidate for the treatment of neurological disorders such as AD and/or schizophrenia.


  • Identification of Novel Small-Molecule ASGP-R Ligands

    by Alexander Majouga, Yan Ivanenkov, Mark Veselov, Anton Lopuhov, Svetlana Maklakova, Elena Beloglazkina, Petr Binevski, Natalya Klyachko, Yuri Sandulenko, Natalia Galkina, et al.

    During the past decade asialoglycoprotein receptor (ASGP-R) expressed predominantly by hepatocytes has attracted a considerable attention as a convenient biomolecular trap for targeted drug delivery. Currently, several selective galactose-containing ligands equipped by drug molecules, e.g. known anticancer therapeutics, as well as diagnostic tools are under active preclinical development. In this paper, we have carried out a rational in silico screening among the molecules available in ChemDiv collection and compounds provided by our colleagues to reveal potential ASGP-R binders. Thus, 3D molecular docking approach provided a set of 100 `high score` molecules that was subsequently evaluated in vitro using an advanced Surface Plasmon Resonance (SPR) technique. As a result, dozens of novel small-molecule ASGP-R ligands with high diversity in structure were identified. Several hits showed the binding affinity much more better than that determined for galactose and N-acetylgalactosamine which were used as reference compounds. The disclosed molecules can be reasonably regarded as promising molecular devices for targeted drug delivery to hepatocytes.


  • Small-molecule PSMA ligands. Current state, SAR and perspectives

    by Alexey E. Machulkin, Yan A. Ivanenkov, Anastasia V. Aladinskaya, Mark S. Veselov, Vladimir A. Aladinskiy, Elena K. Beloglazkina, Victor E. Koteliansky, Artem G. Shakhbazyan, Yuri B. Sandulenko, Alexander G. Majouga

    Prostate cancer (PC) is the prevalent malignancy widespread among men in the Western World. Prostate specific membrane antigen (PSMA) is an established PC marker and has been considered as a promising biological target for anti-PC drug delivery and diagnostics. The protein was found to be overexpressed in PC cells, including metastatic, and the neovasculature of solid tumors. These properties make PSMA-based approach quite appropriate for effective PC imaging and specific drug therapy. Through the past decade, a variety of PSMA-targeted agents has been systematically evaluated. Small molecule compounds have several advantages over other classes, such as improved pharmacokinetics and rapid blood clearance. These low-weight ligands have similar structure and can be divided into three basic categories in accordance with the type of their zinc-binding core-head. Several PSMA binders are currently undergoing clinical trials generally for PC imaging. The main goal of the present review is to describe the recent progress achieved within the title field and structure activity relationships (SAR) disclosed for different PSMA ligands. Recent in vitro and in vivo studies for each type of the compounds described have also been briefly summarized.


  • Synthesis, characterisation, cytotoxicity and antibacterial activity of ruthenium(II) and rhodium(III) complexes with sulfur-containing terpyridines

    by Elena K. Beloglazkina, Eugeniy A. Manzheliy, Anna A. Moiseeva, Olga A. Maloshitskaya, Nikolai V. Zyk, Dmitry A. Skvortsov, Ilya A. Osterman, Petr V. Sergiev, Olga A. Dontsova, Yan A. Ivanenkov, et al.


  • Synthesis, isomerization and biological activity of novel 2-selenohydantoin derivatives

    by Yan A. Ivanenkov, Mark S. Veselov, Igor G. Rezekin, Dmitriy A. Skvortsov, Yuri B. Sandulenko, Marina V. Polyakova, Dmitry S. Bezrukov, Sergey V. Vasilevsky, Maxim E. Kukushkin, Anna A. Moiseeva, et al.


  • Computational insight into the chemical space of plant growth regulators

    by Nikolay A. Bushkov, Mark S. Veselov, Roman N. Chuprov-Netochin, Elena I. Marusich, Alexander G. Majouga, Polina B. Volynchuk, Daria V. Shumilina, Sergey V. Leonov, Yan A. Ivanenkov


  • High throughput screening platform for new inhibitors of protein biosynthesis

    by P. V. Sergiev, I. A. Osterman, A. Ya. Golovina, E. S. Andreyanova, I. G. Laptev, F. I. Pletnev, S. A. Evfratov, E. I. Marusich, M. S. Veselov, S. V. Leonov, et al.


  • Open Access

    Common features of antibacterial compounds: an analysis of 10000 compounds library

    by M.S. Veselov, P.V. Sergiev, I.A. Osterman, D.A. Skvortsov, A.Ya. Golovina, E.S. Andreyanova, I.G. Laptev, P.I. Pletnev, S.A. Evfratov, E.I. Marusich, et al.

    Antibacterial compounds are one of the essential classes of clinically important drugs. High throughput screening allowed revealing potential antibiotics active towards any molecular target in bacterial cell. We used a library of 9820 organic compounds with highly diversified structures to screen for antibacterial activity. As the result of automated screening, 103 compounds were found to possess antibacterial activity against Escherichia coli. The properties of these compounds were compared with those of initial library. Non-linear Kohonen mapping was used to analyze the differences between non-active molecules from initial library, identified antibacterial hits and compounds with reported antibacterial activity. It was found that identified antibacterial compounds are located in the separated area of chemical space. It can be therefore suggested that these molecules belong to novel classes of antibacterial compounds and could be studied further.


  • Recent advances in the synthesis of Fe3O4@AU core/shell nanoparticles

    by Sergei V. Salihov, Yan A. Ivanenkov, Sergei P. Krechetov, Mark S. Veselov, Natalia V. Sviridenkova, Alexander G. Savchenko, Natalya L. Klyachko, Yury I. Golovin, Nina V. Chufarova, Elena K. Beloglazkina, et al.